Medical Imaging Convention [rescheduled] Sep 15, 2021 - Sep 16, 2021 — National Exhibition Centre, Birmingham, England
2021 SINAPSE ASM Sep 16, 2021 - Sep 17, 2021 — Technology & Innovation Centre, University of Strathclyde, 99 George Street, Glasgow
Total Body PET 2021 conference [rescheduled] Sep 22, 2021 - Sep 24, 2021 — Virtual Meeting (online)
PET is Wonderful Annual Meeting 2021 Oct 26, 2021 12:00 AM — Virtual Meeting (online)

eLearning

SINAPSE experts from around Scotland have developed ten online modules designed to explain medical imaging. They are freely available and are intended for non-specialists.


Edinburgh Imaging Academy at the University of Edinburgh offers the following online programmes through a virtual learning environment:

Neuroimaging for Research MSc/Dip/Cert

Imaging MSc/Dip/Cert

PET-MR Principles & Applications Cert

Applied Medical Image Analysis Cert

Online Short Courses

Ms Elisa Calamai

Position: SINAPSE PhD Student
Institute: Institute of Medical Sciences, University of Aberdeen
Department: College of Life Sciences and Medicine


Description of Phd:

 

Alzheimer’s disease (AD) accounts for 62% of all dementia and represents a major and increasing problem in many developed countries. It  is estimated that the cost of dementia care to the NHS is currently £17 billion per annum. Furthermore, as the average age of the population increases these costs are likely to rise significantly. There are currently around 700,000 people in the UK with dementia and this number is expected to rise to over a million by 2025 and over 1.7 million by 2051. Consequently there is significant effort being directed at developing effective treatments for AD. Imaging biomarkers have a significant role to play in this effort. Such treatments will undoubtedly be expensive and current clinical assessment for AD is inaccurate. There is a need for methods that allow specific diagnosis. Specific markers of AD may be used to diagnose patients, to help in drug development, to select patients who are most likely to benefit from a particular therapy or to monitor their response. Positron Emission Tomography (PET) is the most sensitive method for imaging function in-vivo. Therefore, in this project, we aim to develop specific PET imaging biomarkers for AD.

 

Key Publications

B. Platt, E. Calamai, I. Greig, M. Zanda 18F-labelled compounds for use as positron emission imaging agents GB Patent application 1115937.3, 14/09/2011

Elisa Calamai, Sergio Dall’Angelo, David Koss, Juozas Domarkas,Timothy J. McCarthy, Marco Mingarelli, Gernot Riedel, Lutz F. Schweiger,Andy Welch, Bettina Platt, Matteo Zanda 18F-barbiturates are PET tracers with diagnostic potential in Alzheimer's disease Chemical Communications 2013, 49, 792-794.